A short study has shown a correlation in children with IgE-mediated food allergies reporting symptoms of eosinophilic oesophagitis (EoE), leading researchers to suggest that it may be beneficial to screen IgE-FA patients for EoE. Read more
The first UK patient has been recruited for the global MESSINA study for benralizumab for EoE. Find study details and see if you're eligible to take part in the Phase 3 trial. Read more
Allakos has announced that it's ENIGMA (Phase 3) and KRYPTOS (Phase 2/3) studies for lirentelimab in EG & EoD and EoE respectively met histologic endpoints but missed symptomatic endpoints. Read more
The US FDA has rejected an application for TAK-721 (budesonide oral suspension) for the treatment of EoE in it's present form, and have recommended an additional study to help resolve feedback. Read more
The Index, produced by CEGIR researchers, is another step towards global consensus, and is designed to help HCPs monitor EoE severity to make informed decisions about treatment and management. Read more
July 2022 - A trial investigating dupilimab to treat children under 12 with EoE has achieved positive results. This follows the FDA's approval of dupilimab to treat EoE in adults and children 12 and over earlier this year. Read more
Two opportunities are available, a Post-Doctoral Researcher and Research Assistant, in the Allergy, Inflammation & Remodelling Research (AIRR) Laboratory of Dr. Joanne Masterson at Maynooth University, Northern Ireland. Read more
Mar 2021 - Phase 3 trial shows Dupilimab to improve health-related quality of life and reduces symptom burden in patients with EoE. Read more
Mar 2021 - Study finds Budesonide Oral Suspension improves multiple outcomes for children 11-17 with EoE. The drug taken twice-daily improved histologic, endoscopic, and combined histologic and symptomatic outcomes in children with EoE. Read more
Jan 2021 - The International Eosinophil Society (IES) is holding a virtual seminar on 'Eosinophils and COVID'. Talks will include the involvement of eosinophils in viral infections, Covid-19 and eosinophilic diseases, and vaccine hypersensitivity. Read more
Dec 2020 - AstraZeneca has begun its Phase 3 trial evaluating Fasenra in EoE and other eosinophilic diseases. It has also announced a further Phase 3 trial evaluating the drug for EG and EGE. Read more
Nov 2020 - Growing evidence that Eosinophilic Gastritis and Eosinophilic Gastroenteritis are under-diagnosed. 58% of moderate-severely symptomatic patients without diagnoses who entered the ENIGMA study met histologic criteria for EG/EGE Read more
Nov 2020 - Allakos have published the results of the ENIGMA Phase 2 study of Lirentelimab for EG and EGE patients, showing meaningful and statistically significant benefits. The study appears in the October 2020 edition of the NEJM Read more
Oct 2020 - Dupixent® (dupilumab) Late-breaking Pivotal Data Showing Significant Improvement in Eosinophilic Esophagitis Signs and Symptom Read more
May 2020 - USA National Institute of Health Support Research In Covid-19 and Rare Diseases Including Eosinophilic Diseases- Read the full article here Read more
Feb 2020 - Research into blood and tissue markers for EG Eosinophilic Disease study published by CEGIR. Read more